Ibezapolstat Preserves Beneficial Microbiome in Multiply-Recurrent C. difficile, Acurx Data Show
Acurx Pharmaceuticals announced that ibezapolstat preserves beneficial gut microbes in multiply-recurrent C. difficile infection and outperforms standard antibiotics in biofilm killing. A pilot trial in rCDI is set to begin, with plans for FDA approval under the Limited Population Pathway if successful.